Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Determine the effect of treatment with INCB013739 administered as an 'add-on' to metformin therapy in type 2 diabetic subjects on safety and tolerability and glycemic control.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incyte Corporation
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Established diagnosis of Type 2 Diabetes

• Stable dose of metformin for more than 8 weeks

Exclusion Criteria:

• Subjects with Addison's disease or Cushing's Syndrome

• Type 1 diabetes mellitus or secondary forms of diabetes

• Subjects with uncontrolled thyroid disease

• History of renal impairment